Comparison of bleomycin versus Vascular endothelial growth factor inhibitor percutaneous injection in the treatment of extremity vascular anomaly: A randomized control trial

Phase 2

Recruiting

• Conditions: extremity vascular anomaly; hemangioma, vascular anomaly, bleomycin, VEGF inhibitor, bevacizumab

• Registration Number: TCTR20240524002
• Lead Sponsor: Research department, faculty of medicine siriraj hospital, mahidol univerisy

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-24
• Last Update Posted: 19 August 2024
• Study Completion: 2026-04-28

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1.patient that diagnosed infiltrative lesion extremity vascular anomaly by MRI
2.tumor size > 3 cm.
3.pain score 3 points or higher from Visual analog scale (VAS)
4.age 12-80 years old
5.new case or recurrent case

Exclusion Criteria

1. pregnant
2. allergy to contrast media
3. allergy to bleomycin or VEGF inhibitor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
tumor size at 6 and 12 months after intervention MRI

Secondary Outcome Measures

Name	Time	Method
pain score at 6 and 12 months after intervention visual analog scale